Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer

Published:2021-03 Issue:3 Volume:32 Page:395-403
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Perets R.,Bar J.,Rasco D.W.,Ahn M.-J.,Yoh K.,Kim D.-W.,Nagrial A.,Satouchi M.,Lee D.H.,Spigel D.R.,Kotasek D.,Gutierrez M.,Niu J.,Siddiqi S.,Li X.,Cyrus J.,Chackerian A.,Chain A.,Altura R.A.,Cho B.C.

Funder

Merck Sharp and Dohme

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference26 articles.

1. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

2. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors;Hargadon;Int Immunopharmacol,2018

3. Tumor immunotherapy directed at PD-1;Ribas;N Engl J Med,2012

4. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade;Wei;Cell,2017

5. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma;Larkin;N Engl J Med,2015

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Novel Gene Signature based on Immune Cell Infiltration Landscape Predicts Prognosis in Lung Adenocarcinoma Patients;Current Medicinal Chemistry;2024-11

2. The KEYVIBE program: vibostolimab and pembrolizumab for the treatment of advanced malignancies;Future Oncology;2024-09-04

3. First-line treatment with KN046, chemotherapy and palliative radiotherapy for advanced esophageal squamous cell carcinoma: an open-label, dose escalation, and dose expansion phase Ib trial;Cancer Immunology, Immunotherapy;2024-08-06

4. Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy;Journal of Oncology Pharmacy Practice;2024-07-26

5. Tumor immune microenvironment and response of immunotherapy in patients with colorectal cancer;Colorectal Cancer;2024-07-16